No Data
Smart Pharmaceuticals: 2024 Annual Report
Smart Pharmaceuticals: Report for the first quarter of 2025
Smart Pharmaceuticals: 2024 Annual Report Summary
ChemPartner PharmaTech (300149.SZ): Net loss of 0.226 billion yuan in 2024.
On April 28, Gelonghui reported that ChemPartner PharmaTech (300149.SZ) released its annual report for 2024, showing that the company achieved revenue of 0.97 billion yuan in 2024, a year-on-year decrease of 14.77%; the net income attributable to shareholders of the listed company was -0.226 billion yuan. The decline in revenue year-on-year was mainly due to the recovery of the Innovative Drugs Industry being below expectations and intense market competition, which resulted in the company's order acquisition not meeting expectations; the significant year-on-year increase in net income attributable to shareholders of the listed company was mainly due to the reduction in asset impairment provisions compared to the previous year.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
